Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omadacycline Tissue Penetration in Diabetic Wound Infections
NCT04144374Phase 1Completed
- Sponsor
- Hartford Hospital
- Start
- Feb 2020
- Primary completion
- Jul 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of omadacycline in Wound infection (WI) (2 arms), sponsored by Hartford Hospital. Primary endpoint: Omadacycline Tissue Penetration. Started Feb 2020; status: completed.
02
Drugs
omadacycline
03
Conditions
Wound infection (WI)
Beyond the preview
Go deeper on NCT04144374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144374.